FY2025 Earnings Forecast for Bruker Issued By Zacks Research

Bruker Co. (NASDAQ:BRKRFree Report) – Equities researchers at Zacks Research lifted their FY2025 earnings per share estimates for shares of Bruker in a research report issued on Tuesday, March 11th. Zacks Research analyst R. Department now expects that the medical research company will post earnings per share of $2.68 for the year, up from their previous estimate of $2.67. The consensus estimate for Bruker’s current full-year earnings is $2.69 per share.

Bruker (NASDAQ:BRKRGet Free Report) last issued its earnings results on Thursday, February 13th. The medical research company reported $0.76 EPS for the quarter, topping the consensus estimate of $0.75 by $0.01. Bruker had a return on equity of 21.01% and a net margin of 3.36%.

Several other brokerages also recently issued reports on BRKR. Stifel Nicolaus cut their price target on Bruker from $70.00 to $57.00 and set a “hold” rating on the stock in a report on Friday, February 14th. UBS Group started coverage on Bruker in a report on Tuesday, December 10th. They issued a “neutral” rating and a $66.00 price target on the stock. Guggenheim reaffirmed a “buy” rating on shares of Bruker in a research note on Monday, February 24th. Barclays cut their target price on Bruker from $69.00 to $65.00 and set an “overweight” rating on the stock in a research note on Monday, February 10th. Finally, The Goldman Sachs Group raised Bruker from a “sell” rating to a “neutral” rating and set a $60.00 target price on the stock in a research note on Thursday, December 5th. Six investment analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat, Bruker has an average rating of “Moderate Buy” and an average target price of $70.50.

Read Our Latest Research Report on BRKR

Bruker Trading Up 2.2 %

Shares of NASDAQ BRKR opened at $45.97 on Friday. The company has a market cap of $6.97 billion, a price-to-earnings ratio of 60.49, a price-to-earnings-growth ratio of 2.16 and a beta of 1.18. Bruker has a 12-month low of $44.11 and a 12-month high of $94.86. The company has a current ratio of 1.60, a quick ratio of 0.77 and a debt-to-equity ratio of 1.15. The stock’s 50 day simple moving average is $53.66 and its 200 day simple moving average is $58.40.

Bruker Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 28th. Stockholders of record on Monday, March 17th will be paid a $0.05 dividend. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.44%. The ex-dividend date is Monday, March 17th. Bruker’s dividend payout ratio is presently 26.32%.

Institutional Trading of Bruker

Hedge funds and other institutional investors have recently modified their holdings of the company. True Wealth Design LLC raised its stake in shares of Bruker by 4,636.4% in the 3rd quarter. True Wealth Design LLC now owns 521 shares of the medical research company’s stock worth $36,000 after buying an additional 510 shares in the last quarter. Eagle Bay Advisors LLC raised its stake in shares of Bruker by 2,324.1% in the 4th quarter. Eagle Bay Advisors LLC now owns 703 shares of the medical research company’s stock worth $41,000 after buying an additional 674 shares in the last quarter. UMB Bank n.a. raised its stake in shares of Bruker by 37.5% in the 4th quarter. UMB Bank n.a. now owns 909 shares of the medical research company’s stock worth $53,000 after buying an additional 248 shares in the last quarter. Quadrant Capital Group LLC raised its stake in shares of Bruker by 18.2% in the 4th quarter. Quadrant Capital Group LLC now owns 1,273 shares of the medical research company’s stock worth $75,000 after buying an additional 196 shares in the last quarter. Finally, GAMMA Investing LLC grew its holdings in shares of Bruker by 47.5% in the 4th quarter. GAMMA Investing LLC now owns 1,279 shares of the medical research company’s stock worth $75,000 after acquiring an additional 412 shares during the last quarter. Institutional investors own 79.52% of the company’s stock.

Bruker Company Profile

(Get Free Report)

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.

Further Reading

Earnings History and Estimates for Bruker (NASDAQ:BRKR)

Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.